RxDoctor Payments Data

Ahmed Amari, MD

Family Medicine · Visalia, CANPI 1437509296

Payments from drug & device makers

$783in general payments, 2019–2025

Across 43 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$239
  • Lilly USA, LLC$189
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$65
  • Novo Nordisk$60
  • Lundbeck LLC$39
  • Phathom Pharmaceuticals, Inc.$37
  • plus $153 from 7 others

What the payments were for

  • Food & beverage$74495%
  • Education$395%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$783 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$24,261
Medicare patients
67
Services billed
212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide266$252,988
JardianceEmpagliflozin518$248,574
MounjaroTirzepatide236$219,427
EliquisApixaban257$92,159
LinzessLinaclotide129$74,625
RexultiBrexpiprazole103$43,672
RybelsusSemaglutide32$40,143
EntrestoSacubitril/Valsartan114$33,047
Breo ElliptaFluticasone/Vilanterol87$32,443
XifaxanRifaximin35$29,911
TrulicityDulaglutide57$29,065
Synjardy XrEmpagliflozin/Metformin Hcl24$19,978
XareltoRivaroxaban39$19,745
FarxigaDapagliflozin Propanediol26$16,866
Janumet XrSitagliptin Phos/Metformin Hcl29$16,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$60$293,131298 claims
Lilly USA, LLCMounjaro, Trulicity$189$248,492293 claims
PfizerEliquis, Premarin$20$96,879268 claims
Otsuka America Pharmaceutical, Inc.Rexulti$30$43,672103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Visalia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →